U.S. and China regulators have now cleared Sineugene Therapeutics' ALS gene therapy SNUG01 for clinical trials.

First iadademstat clinical trial in non-malignant hematological indications MADRID and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), ...